Education
About Us
Working with TipRanks
Follow Us
GB Sciences Inc (GBLX)
OTHER OTC:GBLX
GBLX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.01 - $0.01
Previous CloseN/A
Volume134.64K
Average Volume (3M)N/A
Market Cap
$81.41K
Enterprise ValueN/A
Total Cash (Recent Filing)$2.32K
Total Debt (Recent Filing)$1.87M
Price to Earnings (P/E)―
Beta-63.04
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding407,071,000
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)-0.49
Price to Sales (P/S)0.00
P/FCF Ratio-2.64
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
GB Sciences News
GBLX FAQ
What was GB Sciences Inc’s price range in the past 12 months?
GB Sciences Inc lowest stock price was $0.01 and its highest was $0.01 in the past 12 months.
What is GB Sciences Inc’s market cap?
GB Sciences Inc’s market cap is $81.41K.
When is GB Sciences Inc’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were GB Sciences Inc’s earnings last quarter?
Currently, no data Available
Is GB Sciences Inc overvalued?
According to Wall Street analysts GB Sciences Inc’s price is currently Overvalued.
Does GB Sciences Inc pay dividends?
GB Sciences Inc does not currently pay dividends.
What is GB Sciences Inc’s EPS estimate?
GB Sciences Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does GB Sciences Inc have?
GB Sciences Inc has 407,071,000 shares outstanding.
What happened to GB Sciences Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of GB Sciences Inc?
Currently, no hedge funds are holding shares in GBLX
Company Description
GB Sciences Inc
GB Sciences, Inc. engages in the research and development of plant-based medicines in North America and Europe. The company offers cannabinoid-inspired medicines and complex therapeutic mixtures for the prescription drug market. Its intellectual property covers a range of conditions and programs in pre-clinical animal stage for Parkinson's disease, neuropathic pain, chronic pain, COVID-related cytokine release syndrome, depression/anxiety, and cardiovascular therapeutic programs. The company was formerly known as Growblox Sciences, Inc. and changed its name to GB Sciences, Inc. in October 2016. GB Sciences, Inc. was incorporated in 2001 and is based in Las Vegas, Nevada.
GB Sciences (GBLX) Earnings & Revenues
Currently, no data available
Please return soon. This page is being updated.
Scorpius Holdings
―
Salarius Pharmaceuticals
―
Processa Pharmaceuticals
―
GRI Bio
―
Onconetix
―
Ownership Overview
―
Insiders
―
Mutual Funds
<0.01% Other Institutional Investors
100.00% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---